Investors deck

August 2026

Forward Looking Statement

This presentation of PolyPid Ltd. (the "Company") contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses statements relating to our objectives, plans, and strategies, the expected timing of trials, the research, development, and use of our platform technologies, technologies, products and product candidates, potential benefits and advantages of our products and product candidates, and all statements (other than statements of historical facts) that address activities, events, or developments that the Company intends, expects, projects, believes, or anticipates will or may occur in the future, the safety, efficacy and benefits of D-PLEx100 ,the expected timing for FDA acceptance letter and PDUFA target date, submission for NTAP reimbursement, EU submission, FDA approval, EU approval, pipeline, US and global addressable market and potential dollar opportunity. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith.

However, there can be no assurance that management's expectations, beliefs and projections will be achieved and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the Securities and Exchange Commission ("SEC"), including, but not limited to, the risks detailed in the Company's Annual Report on Form 20-F, filed with the SEC on February 25, 2026. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements.



Company Snapshot

PolyPid is an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins.

Core Technology
Kynatrix™ Long-Acting, Controlled-Release Technology

Lead Product
D-PLEX$_{100}$ target PDUFA date of November 28, 2026

Unique Value
Customizable controlled release, linear delivery of APIs

Next big opportunity
Ultra long GLP-1 Receptor Agonist

Patents
176* granted & pending

Employees
~80* employees

Publicly Traded
NASDAQ: PYPD

Built for Scale
GMP-certified 18,000 sq ft commercial-ready facility

*As of May 2026

polypid

The Power of Uncompromising Precision




Substance Versatility
Suitable for antibiotics, cytotoxic agents, peptides, nucleic acids, and more.



Zero-Burst Release
No initial drug spike



Customizable Duration
Tunable from several days to several weeks.



Layered Matrix Architecture
Controlled sequential disintegration.



Scalable Manufacturing Process
Designed for consistent quality and commercial-scale production.



Minimal Systemic Exposure
Reduced toxicity and side effects.


PolyPid


Introducing the Kynatrix™ Technology


Introducing The Kynatrix Technology



Drug molecules are embedded within the alternating polymer-lipid layers



Body moisture activates the platform, triggering controlled surface degradation of the polymer-lipid matrix and constant, linear drug release.



Release is sustained and customizable for days to weeks

PolyPid



Portfolio Flagship Product: D-PLEX$_{100}$

What is it?
A high-concentration doxycycline formulation (broad-spectrum antibiotic) delivered locally over 30 days.

Indication for Use
Prevention of surgical site infections (SSIs) following abdominal colorectal surgery.

Prevalence: 15%–25% SSI in abdominal surgery
Colorectal surgery, large incisions, and patients with obesity, diabetes, or immunocompromised have a higher risk of infection.

Administration
Applied at the time of surgical closure, with dosing determined by the length of the surgical incision

Regulatory status – NDA under FDA review
Breakthrough Therapy, Fast Track, and QIDP designations, FDA 505(b)(2)

Easily Applied in Any Surgical Setting

Instruction for use:



D-PLEX$_{100}$ applied in abdominal surgery:



The Largest Phase III Trial for Prevention of SSI in Over a Decade




Population
Patients undergoing elective abdominal colorectal surgery with incision length > 20 cm

Primary efficacy endpoint
Reduction in SSI, mortality and reintervention within 30 days post index surgery

Trial size
Global trial US, Europe
ITT cohort: 798 patients

Phenomenal Phase III Clinical Trial Results



RRR = relative risk reduction

A Potential Multi-Million-Dollar Opportunity



12M/Year

US total addressable market in-patient surgical procedures

4.4M/Year

Abdominal Surgeries

Includes colorectal, gyn, urology, and high-risk procedures

**Source IQVIA PM&I Global FlexView. Internal analysis

Azurity Partnership Valued at >$320M

U.S. and Canada Commercial Partnership

FINANCIAL TERMS

Upfront Payment:
$30M in upfront and near-term milestone payments: $15M at signing and $15M upon FDA acceptance (expected Aug. 2026)

>$290M Development & Sales Milestones

Royalties
Tiered royalties on net sales ranging from mid-teen to mid-twenties percentages

Pre-Negotiated Transfer Price

Partner to Fund Clinical Development For Label Expansion

DEAL STRUCTURE

Scope
U.S. and Canada. PolyPid retains rights for all other territories

Azurity Responsibilities:
Lead all commercial activities necessary for launch and continued growth or D-PLEX$_{100}$ in these markets

PolyPid Responsibilities:
Manufacturing and supply of D-PLEX$_{100}$

Jointly pursue label expansion of D-PLEX$_{100}$ into SSI indications beyond abdominal



Demonstrated Economic Incentive to Drive Adoption

Direct cost

SSI costs ~$30K/patient[1] on average

- Prolonged length of stay and higher readmission rates
- Re-operation in some cases (to debride and remove infected / necrotic tissues)

Indirect cost

CMS 1-3% penalty on all the yearly Hospital Medicare reimbursement

Reputational cost


Hospital SSI rates are public information and have direct influence on hospital ranking by CMS and U.S. News best hospitals ranking

D-PLEX$_{100}$ is eligible for NTAP program:
up to 75% reimbursement of cost of drug

1. Stone PW. Economic burden of healthcare-associated infections: an American perspective. Expert Rev Pharmacoecon Outcomes Res. 2009 Oct;9(5):417-22.

Surgeons perceive D-PLEX$_{100}$ to be more valuable overall than currently used interventions

How likely are you to prescribe D-PLEX$_{100}$ to prevent SSIs in eligible surgical patients? (% of responders)



Most Mentioned Patients Appropriate for D-PLEX$_{100}$

Patient with a higher risk of infection immunocompromised, comorbidities, obese, uncontrolled diabetics, transplant patients

Patients undergoing Colorectal Surgeries


Any procedure with incisions >10 cm

F/S – On Formulary & Stocked; F/NS = On Formulary, but NOT Stocked; NF/NS = Not on Formulary & Not Stocked

Source: Indegene Market Research October 2025

Pharmacy Directors expect high likelihood of formulary coverage and stocking of D-PLEX$_{100}$

Value perception and **likelihood for formulary coverage** and stocking are high and grow even higher with the introduction of **NTAP**



Manufacturing Excellence Enabling Global Scale

PolyPid operates an 18,000 sq. ft., state-of-the-art GMP facility purpose-built for its .proprietary Kynatrix™ drug-delivery technology

The site enables precise, reproducible production of our proprietary formulations and supports scalable manufacturing from clinical to commercial volumes, .ensuring consistent product performance and global supply readiness






Always Delivering, Our Milestones Too

Expected Timeline



✓ **July 2026**
NDA Submission - Accepted

↓ **Q3 2026**
EU Submission

↓ **Oct. 2026**
Submission for NTAP reimbursement

↓ **Nov. 28, 2026**
PDUFA Target date

↓ **Early 2027**
Expected launch

↓ **H2 2027**
EU approval

✓ Completed
Phase 3 Global SHIELD II Trial

- Reached primary and all key secondary endpoints
- ~60 global clinical sites

✓ Completed
Full CMC & GMP Readiness

State-of-the-art 18,000 sq ft GMP manufacturing facility certified by Israel MoH & EU Qualified Person

✓ NDA Submission Completed

- PDUFA target date: November 28, 2026

polypid

Innovation Strategy

Our strategy is to leverage the power of our KynatriX™ delivery technology to elevate treatment effectiveness

Collaborate with R&D partners to:



Improve efficacy



Extend molecule ½ life



Eliminate systemic side effects and toxicity

Key Therapeutic Areas

- Surgical Site Infection
- Infection Treatment
- Metabolic Diseases & Obesity

polypid

Innovation Pipeline

Current Pipeline

Therapeutic Area	Product name	Pre-Clinical	Phase 1	Phase 2	Phase 3	Regulatory Review	In-house / partnership
SSI	D-PLEX$_{100}$						In-house
Metabolic Disease	PP03A						In-house
Oncology	PP04A						IMMUNOGENESIS

Indicated for prevention of surgical site infections (SSIs) following abdominal colorectal surgery. PDUFA target date November 28, 2026.

Ultra-long GLP-1 receptor agonist released over +50 days in a linear manner overcoming the peak and trough release profile seen in current weekly injection therapy.

Intratumoral delivery of Immunogenesis potent anti-tumor STING agonist combined with PolyPid's delivery technology to enhance treatment for solid tumors.

PolyPid

Financials



Stock Information	
Listing	NASDAQ
Ticker	PYPD
52-week range[1]	$3.06-$5.73
Market cap[1]	$110 M
Share Structure[2]	
Shares outstanding	20.3 M
Shares held in abeyance	2.8 M
Warrants (Expired Aug. 6, 2026)	0.5 M @ $3.61 exercise price
Warrants	7.3 M @ $4.50 exercise price
Options outstanding	3.6 M @ $4.7 WAEP



Analyst coverage

CRAIG-HALLUM CAPITAL GROUP LLC

Citizens Bank®

ROTH

HCW H.C.WAINWRIGHT&CO.

1. As of August 12, 2026
2. As of June 30, 2026

PolyPid

Built for Scale and Growth



Large, Attractive Market Opportunity

Addressing a substantial global market of 12M surgeries annually with significant unmet need in surgical site infection prevention.

Multiple Near-Term Catalysts

Expected PDUFA date November 28, 2026

Innovation-Driven Pipeline

A growing pipeline built on PolyPid's differentiated Kynatrix™ technology, enabling expansion into additional high-value indications beyond the lead program.

Thank You!

PolyPid